Kite’s Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings – Gilead Sciences (NASDAQ:GILD)Yahoo Finance · 17:17 09 Feb 2023Kite, a Gilead Sciences Inc GILD company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleuc… Read More
